Skip to content

Renal Resistive Index as a Predictor of Acute Kidney Injury and Evaluation of Fluid Administration in Sepsis

Renal Resistive Index by Renal Doppler Ultrasound as a Predictor of Acute Kidney Injury and Evaluation of Fluid Administration in Sepsis Patients: Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06009445
Enrollment
45
Registered
2023-08-24
Start date
2023-07-01
Completion date
2024-07-01
Last updated
2023-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Renal Resistive Index, Sepsis

Brief summary

We aim from this study to investigate the role of renal resistance index (RRI) in evaluation of Acute kidney injury development and fluid administration in sepsis patients considering the change in RRI values over 7 days from admission as a predictor of AKI development

Detailed description

Acute kidney injury (AKI) is one of the most common problems in critically ill patients in the clinic. AKI can be caused by various factors, such as hypovolemia, shock, major surgery, trauma, and heart failure, of which sepsis is the most common

Interventions

DIAGNOSTIC_TESTRenal resistive index

The calculation formula for Renal resistive index (RRI) as follows : (systolic peak flow velocity \_ diastolic minimum flow velocity )/systolic peak flow velocity . will be measured with ultrasound-Doppler using an abdominal curvilinear probe ultrasonography by two independent, trained sonographers (who will not be involved in patient care. After visualizing the kidney in ultrasound mode and checking for renal abnormalities, an arcuate or interlobar artery will be localized and three successive doppler measurements at different positions in the kidney (high, middle and low) will be performed, 3 times in each kidney. So a total number of 9 RRI values will be obtained in each kidney. The median value of each section will be used and the 3 median values of each kidney will be averaged.

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age over 21 years * meet Sepsis 3 criteria (potential source of infection , host response and organ dysfunction) but not in septic shock.

Exclusion criteria

* patients during pregnancy. * patients with hepatorenal syndrome. * Poor abdominal echogenicity eg.(morbid obesity ,increase intra abdominal pressure ) * Severe acute or chronic renal insufficiency . * Dialysis dependency. * Renal transplantation. * Known renal artery stenosis. * Mono-kidney, kidney tumor, anatomic kidney abnormalities.

Design outcomes

Primary

MeasureTime frameDescription
Prediction of AKI development by renal resistance index (RRI)7 days from admissionAKI was defined according to the Kidney Disease Improving Global Outcome (KDIGO) classification using both creatinine and urine output criteria. The KDIGO guidelines define AKI as follows * Increase in serum creatinine by ≥0.3 mg/dL (≥26.5 micromol/L) within 48 hours, or * Increase in serum creatinine to ≥1.5 times baseline, which is known or presumed to have occurred within the prior seven days, or * Urine volume \<0.5 mL/kg/hour for six hours

Secondary

MeasureTime frameDescription
Evaluation of fluid administration7 days from admissionRRI and other hypoperfusion markers after fluid challenge and divided into responder to fluid (Time 1 F) and non responder with noradrenaline administration (Time 1 N) .
Length of ICU stay2 months from admission till dischargeLength of ICU stay till discharge will be measured.
cumulative fluid balance over 7 days7 days from admissionCumulative fluid balance over 7 days and urine output (intake -output) will be measured.
The incidence of 28 day mortality28 days from admissionThe incidence of mortality will be measured at 28 day.

Countries

Egypt

Contacts

Primary ContactSafinaz A Aboelfetoh, MBBCh
noralamar34@gmail.com00201148855752

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026